Naratriptan Arrow (Naratriptan Hydrochloride)

The active ingredient, Naratriptan Hydrochloride, acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors, it causes constriction of dilated cranial blood vessels and blocks the release of pain‑triggering neuropeptides, thereby interrupting the migraine pain pathway.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Naratriptan Hydrochloride in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naratriptan is a second‑generation triptan with a relatively long half‑life, offering sustained relief for many patients. Compared with earlier triptans, it may have a lower incidence of cardiovascular side effects, but individual response varies, and clinicians choose therapy based on efficacy, tolerability, and patient comorbidities.

Naratriptan Arrow should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

The medication is taken orally, usually as a single tablet at the onset of migraine symptoms. It should be swallowed whole with a glass of water and not crushed or chewed. Patients should follow the prescriber’s guidance on timing and any repeat dosing limits.

Serious risks include the potential for serotonin syndrome when combined with other serotonergic drugs, severe cardiovascular events such as myocardial infarction or stroke in patients with underlying vascular disease, and rare allergic reactions that may require immediate medical attention.

Naratriptan Arrow is contraindicated in patients with uncontrolled hypertension, recent myocardial infarction or stroke, known hypersensitivity to naratriptan or any component of the formulation, and in those taking monoamine oxidase inhibitors within the past two weeks.